tradingkey.logo
tradingkey.logo
Search

CorMedix Inc

CRMD
Add to Watchlist
7.530USD
+0.040+0.53%
Close 07-31 16:00ETQuotes delayed by 15 min
590.74MMarket Cap
3.10P/E TTM

More Details of CorMedix Inc Company

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.

CorMedix Inc Info

Ticker SymbolCRMD
Company nameCorMedix Inc
IPO dateMar 25, 2010
CEOTodisco (Joseph)
Number of employees64
Security typeOrdinary Share
Fiscal year-endMar 25
Address300 Connell Drive
CityBERKELEY HEIGHTS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code07922
Phone19085179500
Websitehttps://cormedix.com/
Ticker SymbolCRMD
IPO dateMar 25, 2010
CEOTodisco (Joseph)

Company Executives of CorMedix Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Joseph (Joe) Todisco
Mr. Joseph (Joe) Todisco
Chief Executive Officer, Director
Chief Executive Officer, Director
401.08K
-41.48%
Ms. Susan Blum
Ms. Susan Blum
Chief Financial Officer
Chief Financial Officer
132.74K
+47.50%
Mr. Steven W. Lefkowitz
Mr. Steven W. Lefkowitz
Independent Director
Independent Director
127.65K
-4.27%
Ms. Janet M. Dillione
Ms. Janet M. Dillione
Independent Director
Independent Director
38.47K
-14.17%
Mr. Gregory Scott (Greg) Duncan
Mr. Gregory Scott (Greg) Duncan
Independent Director
Independent Director
38.33K
-14.23%
Mr. Robert Stewart
Mr. Robert Stewart
Independent Director
Independent Director
36.00K
-15.15%
Mr. Myron M. Kaplan, J.D.
Mr. Myron M. Kaplan, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Alan William Dunton, M.D.
Dr. Alan William Dunton, M.D.
Independent Director
Independent Director
--
--
Ms. Elizabeth (Liz) Massonhurlburt
Ms. Elizabeth (Liz) Massonhurlburt
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Matthew T. (Matt) David, M.D.
Dr. Matthew T. (Matt) David, M.D.
Chief Business Officer
Chief Business Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Joseph (Joe) Todisco
Mr. Joseph (Joe) Todisco
Chief Executive Officer, Director
Chief Executive Officer, Director
401.08K
-41.48%
Ms. Susan Blum
Ms. Susan Blum
Chief Financial Officer
Chief Financial Officer
132.74K
+47.50%
Mr. Steven W. Lefkowitz
Mr. Steven W. Lefkowitz
Independent Director
Independent Director
127.65K
-4.27%
Ms. Janet M. Dillione
Ms. Janet M. Dillione
Independent Director
Independent Director
38.47K
-14.17%
Mr. Gregory Scott (Greg) Duncan
Mr. Gregory Scott (Greg) Duncan
Independent Director
Independent Director
38.33K
-14.23%
Mr. Robert Stewart
Mr. Robert Stewart
Independent Director
Independent Director
36.00K
-15.15%

FAQs

Who are the top five shareholders of CorMedix Inc?

The top five shareholders of CorMedix Inc are: Mr. Joseph (Joe) Todisco

How many institutions hold shares of CorMedix Inc (CRMD)?

As of 2026Q1, 390 institutions hold shares of CorMedix Inc, with a combined market value of approximately 43.28M, accounting for 55.17% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -18630389.00.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.